Acelyrin said Thursday that has filed for an initial public offering.
The late stage clinical biopharmaceutical company is offering 30 million shares of common stock at a price of $18 each.
It applied to list its shares on the Nasdaq Global Select Market under the symbol SLRN.
The…
Read the full article here